Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating glioblastoma.
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
Northwestern Medicine scientists have developed a novel testing platform to assess, in real time, the efficacy of nanomaterials in regulating gene expression.
Revolutionary nanomaterials developed at Northwestern could make it possible to repair tissues and organs spanning from bone and cartilage to muscle and brain tissues.
Northwestern Medicine scientists have demonstrated an enhanced approach to targeting a type of inflammatory cell involved in atherosclerosis.
A Northwestern University research team is developing a tool to rapidly test millions and perhaps even billions or more different nanoparticles at one time to zero in on the best particle for a specific use, including for medical applications.